Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.

Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment ...

On Monday, the FDA said Sarepta may resume treating ambulatory Duchenne patients with Elevidys. The recommendation comes just ...

Sarepta Therapeutics said on Monday it will resume shipping of its gene therapy Elevidys to patients with a rare muscular ...

The FDA has partially reversed course on its push to halt shipments of a controversial gene therapy made by Sarepta ...

The U.S. Food and Drug Administration said on Monday it is recommending the removal of the hold placed on Sarepta ...

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previo ...

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ...

NEW YORK, July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit ...

Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky Provided by GlobeNewswire Jul 11, 2025, 1:22:00 PM ...